Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche

Figure 2

PCSD1 tumor growth was significantly greater in the bone niche compared to sub-cutaneous niche. Tumor growth was compared as a function of tumor volume per cell injected at transplantation. The same tumor volumes were attained in the same time when 50,000 PCSD1 cells were injected intra-femorally as when one million PCSD1 cells were injected sub-cutaneously. A. Final tumor volume of sub-cutaneous (SC) and intra-femoral (IF) tumors per initially injected cell number. Blue bars show final tumor volume per injected cell in mice treated with vehicle control, Red bars are for mice treated with bicalutamide. There was a 24-fold greater tumor volume per IF-injected cell compared to SC-injected cell in vehicle treated mice and a 16-fold greater tumor volume in bicalutamide treated IF versus SC injected tumors. B. Final tumor volume of sub-cutaneous (SC) tumors per initially injected cell number. Error bars show standard deviation.

Back to article page